Ken Griffin Centessa Pharmaceuticals PLC Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$8.58 - $16.99 $53,196 - $105,337	-6,200 Reduced 51.24%	5,900 $94,000
Q2 2024 Aug 14, 2024	SELL	$8.04 - $11.87 $45,023 - $66,472	-5,600 Reduced 31.64%	12,100 $109,000
Q1 2024 May 15, 2024	BUY	$6.73 - $12.2 $54,513 - $98,820	8,100 Added 84.38%	17,700 $200,000
Q4 2023 Feb 14, 2024	BUY	$5.52 - $8.03 $14,351 - $20,878	2,600 Added 37.14%	9,600 $76,000
Q3 2023 Nov 14, 2023	BUY	$6.01 - $8.24 $34,858 - $47,792	5,800 Added 483.33%	7,000 $45,000
Q2 2023 Aug 14, 2023	BUY	$3.68 - $6.9 $4,416 - $8,280	1,200 New	1,200 $7,000

108

118M

5.9K

53K

Ticker CNTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,339,296
Market Cap $1.59B
Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.